secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001628280-23-028289
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Pharma Q2 revenue $10.9M (+6% YoY); net income $0.9M
---------------------------------------------------------------

- Q2 net revenue $10.9M (+6% vs prior year, +18% sequential); YTD revenue $20.1M.
- Q2 net income $0.9M ($0.06/diluted share); YTD net income $1.1M ($0.07/share).
- Adjusted Q2 earnings $2.3M ($0.16/share); YTD adjusted $4.0M ($0.27/share).
- FDA approved Caldolor for infants (3-6 months) in May; study results published June.
- Received $2.8M in FDA barrier-to-innovation fee waivers in June 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828023028289/0001628280-23-028289-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828023028289/cpix-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-028289

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer